Related Experiment Videos
Radiolocalization of human prostate tumor in a mouse subrenal capsule model by monoclonal antibody TURP-27
G L Wright1, E Wilson, M Klinger
1Department of Microbiology and Immunology, Eastern Virginia Medical School, Norfolk 23501.
Abstract:
The subrenal capsule assay was used to determine if 125I-labeled anti-prostate monoclonal antibody TURP-27 could target human prostate tumor fragments implanted under the renal capsule of normal immunocompetent C57 BL/6 mice. Maximal binding and optimal tumor to non-tumor tissue ratios occurred within 24-48 hours postadministration of 125I-TURP-27. No significant localization was observed in mice bearing TURP-27 antigen-negative human colon tumor tissue implants or with an isotype-matched control monoclonal antibody. These preclinical data suggest that TURP-27 may have clinical application for imaging metastatic prostate tumors and further application in immunoconjugate and/or radiotherapy of prostate cancer.
Insights
The anti-prostate antibody TURP-27 effectively targets human prostate tumors in mice. This antibody shows promise for imaging and treating prostate cancer.
Area of Science:
- Oncology
- Immunology
- Radiopharmaceuticals
Background:
- Prostate cancer remains a significant health concern with a need for improved diagnostic and therapeutic agents.
- Monoclonal antibodies offer targeted delivery of payloads for cancer treatment and imaging.
- The TURP-27 antibody targets a specific antigen found on prostate tumor cells.
Purpose of the Study:
- To evaluate the targeting efficacy of 125I-labeled anti-prostate monoclonal antibody TURP-27 against human prostate tumor xenografts in vivo.
- To determine the optimal timing for maximal tumor binding and tumor-to-non-tumor tissue ratios.
- To assess the specificity of TURP-27 targeting.
Main Methods:
- Subrenal capsule assay in immunocompetent C57 BL/6 mice.
- Implantation of human prostate tumor fragments.
- Administration of 125I-labeled TURP-27 monoclonal antibody.
- Comparison with TURP-27 antigen-negative colon tumor xenografts and control antibodies.
Main Results:
- Maximal binding of 125I-TURP-27 to prostate tumor fragments was observed within 24-48 hours.
- Optimal tumor to non-tumor tissue ratios were achieved at 24-48 hours post-administration.
- No significant localization was observed in colon tumor xenografts or with control antibodies, indicating high specificity.
Conclusions:
- 125I-labeled TURP-27 demonstrates specific and effective targeting of human prostate tumor xenografts in a preclinical model.
- The antibody's pharmacokinetic profile supports its potential for imaging metastatic prostate cancer.
- TURP-27 holds promise for future applications in prostate cancer immunoconjugate therapy and radiotherapy.